AD01 is a proprietary combination of topiramate and ondansetron, and shows a benefit for 1 out of 2 patients treated vs. currently marketed drugs that only benefit (approximately) 1 out of 10.
|Pre-clinical*||First trials undertaken to determine drugs effects conducted in a laboratory or through controlled animal studies.||completed|
|Phase 0*||First-in-human trials undertaken to provide an early indication of new drugs effects in humans.||completed|
|Phase I*||Limited number human trials aimed at evaluating the safety, tolerability and effects of a new drug.||completed|
|Phase II*||Limited number of human trials undertaken to evaluate the effect of the combination drug vs either drug alone and vs placebo.||underway||Target completion date for this 320 patient study is the 3rd Quarter 2012.|